Image

Wideband Tympanometry as a Non-behavioral Test of the Speech-weighted Middle Ear Transfer Function.

Wideband Tympanometry as a Non-behavioral Test of the Speech-weighted Middle Ear Transfer Function.

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

There is a need for a non-behavioral clinical test that provides an assessment of how speech is conducted through the middle ear for the optimization of middle ear implants. These implants utilize the functionality of the human middle ear and require adequate speech conduction through the middle ear chain. Consequently, the clinical test of this degree of speech transfer can contribute to the pre-operative indication for middle ear implants.

Wideband Tympanometry (WT) is a non-invasive diagnostic tool for the clinical assessment of the condition of the middle ear. Unlike classical tympanometry, WT tests the impedance of the middle ear system as a function of both pressure and frequencies. Consequently, a WT measurement contains many times more information about the functionality of the middle ear than classical tympanometry and is ideally suited as a diagnostic tool for the clinical assessment of speech transfer through the middle ear. The WT measurements will be correlated with the Speech Intelligibility Index (SII) collected in normally hearing individuals and patients with isolated conductive hearing loss. This index is a measure of speech transfer through the middle ear. Consequently, a correlation of the WT measurements with the SII addresses the need for a non-behavioral clinical test of speech transfer through the middle ear.

Additionally, WT measurements will be performed longitudinally in cochlear implant candidates, one of the populations that can benefit from the developed clinical test. These longitudinal WT measurements, which will be performed both pre- and post-operatively, allow for the evaluation of the impact of middle ear surgery on the predicted SII.

Eligibility

Inclusion Criteria:

  • NH subjects
  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • At least 18 years of age at the time of signing the ICF.
  • Pure tone audiometry:
  • Air-conduction hearing threshold at all frequencies ≤15dB.
  • No air-bone-gap.
  • Normal classical tympanometry: Jerger A (see fig. 1)
  • CHL subjects
  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • At least 18 years of age at the time of signing the ICF.
  • Pure tone audiometry:
  • Bone-conduction threshold at all frequencies ≤20dB.
  • Two exceptions:
    • Age-related hearing loss: bone-conduction threshold ≤40dB in the higher frequencies (\> 2kHz).
  • Carhart notch: bone-conduction threshold \>20dB around 2kHz. air-bone-gap ≥10dB at ≥ 1 frequency.
  • CI recipients
  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • At least 18 years of age at the time of signing the ICF.
  • Ear is planned for CI surgery by treating ENT surgeon.
  • Normal classical tympanometry: Jerger A.

Exclusion Criteria

  • NH subjects
  • Patient has history of extensive middle ear disease.
  • Patient has history of middle ear surgery.
  • Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion.
  • Severe otitis externa or occlusion of the external auditory canal
  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device
  • CHL subjects
  • Patient has history of middle ear surgery.
  • Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion.
  • Signs of structural pathological processes such as tumors, cysts or cholesteatoma.
  • Severe otitis externa or occlusion of the external auditory canal
  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device
  • CI recipients
  • ear has history of extensive middle ear disease.
  • ear has history of middle ear surgery.
  • Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion.
  • Severe otitis externa or occlusion of the external auditory canal

Study details
    Conductive Hearing Loss

NCT07557771

Universitaire Ziekenhuizen KU Leuven

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.